Eyal Talor Ph.D.
Net Worth
Last updated:
What is Eyal Talor Ph.D. net worth?
The estimated net worth of Dr. Eyal Talor Ph.D. is at least $8,529,081 as of 19 Oct 2021. He owns shares worth $905,278 as insider, has earned $564,883 from insider trading and has received compensation worth at least $7,058,920 in CEL-SCI Corporation.
What is the salary of Eyal Talor Ph.D.?
Dr. Eyal Talor Ph.D. salary is $320,860 per year as Chief Scientific Officer in CEL-SCI Corporation.
How old is Eyal Talor Ph.D.?
Dr. Eyal Talor Ph.D. is 69 years old, born in 1956.
What stocks does Eyal Talor Ph.D. currently own?
As insider, Dr. Eyal Talor Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| CEL-SCI Corporation (CVM) | Chief Scientific Officer | 104,899 | $8.63 | $905,278 |
What does CEL-SCI Corporation do?
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Eyal Talor Ph.D. insider trading
CEL-SCI Corporation
Dr. Eyal Talor Ph.D. has made 16 insider trades between 2003-2021, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of CVM stock worth $168,750 on 19 Oct 2021.
The largest trade he's ever made was exercising 100,000 units of CVM stock on 5 Jun 2009. As of 19 Oct 2021 he still owns at least 104,899 units of CVM stock.
CEL-SCI key executives
CEL-SCI Corporation executives and other stock owners filed with the SEC:
- Dr. Daniel H. Zimmerman Ph.D. (84) Senior Vice President of Research & Cellular Immunology
- Dr. Eyal Talor Ph.D. (69) Chief Scientific Officer
- Mr. Geert R. Kersten (66) Chief Executive Officer, Principal Accounting & Financial Officer, Treasurer and Director
- Mr. John Cipriano (83) Senior Vice President of Regulatory Affairs
- Ms. Patricia B. Prichep (74) Senior Vice President of Operations & Corporation Sec.